Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.57 |
| ▸ | MMP1 | P03956 | 8/20 | 0.57 |
| ▸ | MMP9 | P14780 | 7/20 | 0.57 |
| ▸ | MMP2 | P08253 | 6/20 | 0.57 |
| ▸ | MMP3 | P08254 | 6/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.57 |
| ▸ | MMP7 | P09237 | 4/20 | 0.57 |
| ▸ | BMP1 | P13497 | 6/20 | 0.51 |
| ▸ | ADAMTS7 | Q9UKP4 | 2/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808879 | 0.92 | MMP13 (0.58) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6294163 | 0.92 | MMP13 (0.62) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6810494 | 0.90 | MMP13 (0.59) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6294208 | 0.85 | MMP13 (0.61) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7346511 | 0.85 | MMP9 (0.58) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7346519 | 0.85 | MMP9 (0.58) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7346440 | 0.84 | MMP9 (0.54) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7346436 | 0.84 | MMP9 (0.54) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6290473 | 0.83 | MMP13 (0.65) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7046221 | 0.81 | MMP13 (0.58) | MMP13MMP1MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP9 3/4885 |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.